Iraida Loinaz, coordinator of the PneunoNP project, attends the EuroNanoForum 2017 conference.
EuroNanoForum 2017 is an international event that focus on how nano and materials technologies can strengthen competitiveness across all European industries. The event takes place in Malta from 21th and 23th June 2017.
Nanotechnology is expected to gain importance in the near future in many industries. For example, nanomedicine could solve numerous healthcare challenges especially in the field of drug-delivery. However, from the pharmaceutical point of view, there is insufficient clinical data that allows the assessment of the role of nanotechnology in the potential of these products.
It is time to push those promising developments to the clinical stage. Iraida Loinaz’s talk will show real examples on how is possible to translate a lab scale protocol, into a robust GMP manufacturing process, and those key aspects to take into account to reduce the time of development.
Iraida Loinaz, coordinator of PneunoNP project, is the Health business development Manager of IK4-Cidetec. In the last years Dr. Loinaz’s group has been specialized in translational research. They are establishing a pilot plant operating under GMP for the production of nanopharmaceuticals.
“It is my first time attending EuroNanoForum,” Dr Loinaz said. “I really look forward to meeting main stakeholders in the field of nanotechnologies for health and share our experiences in the field.”
Find all the necessary information related to the event on: www.eccmid.org.
An experiment carried out in Spain shows the distribution of an inhaled nanomedicine in rat lungs.
The PneumoNP project aims at developing new inhaled nanotherapeutic formulations to combat lung infection. The novel drug is comprised of an antibiotic carried by a nanoparticle. For this project, Spanish researchers from CIC BiomaGUNE track the location of the therapeutic particles in rat airways.
The use of nanoparticles in formulations is anticipated to lengthen the residence time of the drug in lungs. Indeed, it is expected to slow down and control the release of the active molecules. This prevents rapid metabolism and fast clearance. So, the therapeutic effects are expected to increase. Besides, the delivery by inhalation contributes to diminish undesired toxicological and off-target side effects. The results obtained in imaging experiments are essential to establish the appropriate dosage to be used in therapeutic experiments with infected animals and to predict therapeutic efficacy.
Positron emission tomography image showing the regional distribution of aerosolized nanocarrier-antibiotic formulation in rat lung.
The researchers have developed labeling methods to incorporate different radionuclides to the nanocarrier and the antibiotic. Thanks to the different physical properties of the radionuclides, they visualize the spatiotemporal distribution of the nanocarrier and the antibiotic separately. To achieve that they also used complementary in vivo imaging modalities.
From imaging experiments, relevant information can be determined quantitatively by using only few experimental animals and extremely refined procedures. The percentage of administered dose that reaches the lungs is important to assess the efficacy of the aerosol delivery method. The researcher looks also for the regional distribution of the antibiotic and the nanocarrier within the lungs. With the spatiotemporal imaging, they evaluated the residence time of the active drug and the nanocarrier in the lungs.